ProShare Advisors LLC Grows Stock Position in Insmed Incorporated (NASDAQ:INSM)

ProShare Advisors LLC lifted its stake in Insmed Incorporated (NASDAQ:INSM - Free Report) by 43.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 56,991 shares of the biopharmaceutical company's stock after purchasing an additional 17,141 shares during the period. ProShare Advisors LLC's holdings in Insmed were worth $3,935,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Steward Partners Investment Advisory LLC increased its holdings in Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 163 shares during the last quarter. V Square Quantitative Management LLC increased its holdings in Insmed by 60.3% in the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 248 shares during the last quarter. Spire Wealth Management purchased a new position in Insmed in the fourth quarter valued at $47,000. Smartleaf Asset Management LLC increased its holdings in Insmed by 98.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 411 shares during the last quarter. Finally, Venturi Wealth Management LLC purchased a new position in Insmed in the fourth quarter valued at $86,000.

Insmed Price Performance

Shares of INSM opened at $67.88 on Tuesday. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $84.91. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The firm has a 50-day simple moving average of $71.45 and a 200-day simple moving average of $73.16. The company has a market capitalization of $12.36 billion, a price-to-earnings ratio of -12.14 and a beta of 0.84.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company had revenue of $92.82 million for the quarter, compared to analysts' expectations of $91.63 million. During the same quarter last year, the company earned ($1.06) EPS. Insmed's revenue for the quarter was up 22.9% compared to the same quarter last year. On average, equities research analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current year.

Insider Transactions at Insmed

In related news, CFO Sara Bonstein sold 8,870 shares of Insmed stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $67.81, for a total value of $601,474.70. Following the sale, the chief financial officer now directly owns 109,993 shares in the company, valued at $7,458,625.33. The trade was a 7.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO William Lewis sold 18,750 shares of Insmed stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $77.79, for a total value of $1,458,562.50. Following the completion of the sale, the chief executive officer now owns 334,186 shares in the company, valued at approximately $25,996,328.94. This trade represents a 5.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 125,211 shares of company stock worth $8,837,158 over the last ninety days. 3.00% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently issued reports on INSM shares. Truist Financial upped their price target on Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a report on Friday, February 21st. HC Wainwright reaffirmed a "buy" rating and issued a $90.00 price target on shares of Insmed in a report on Monday, May 12th. Cantor Fitzgerald reissued an "overweight" rating on shares of Insmed in a research report on Wednesday, February 19th. UBS Group reduced their price target on shares of Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $100.00 price target on shares of Insmed in a research report on Wednesday, March 19th. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $94.63.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed Incorporated (NASDAQ:INSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.